EMA's human medicines committee (CHMP) has approved additional manufacturing sites for the production of Comirnaty, the COVID-19 vaccine developed by
One site, located in
These sites will provide up to 50 million additional doses in 2021.
These recommendations do not require a
EMA is in continuous dialogue with all marketing authorisation holders of COVID-19 vaccines as they seek to expand their production capacity for the supply of vaccines. The Agency provides guidance and advice on the evidence required to support and expedite applications to add new sites or increase the capacity of existing sites for the manufacture of high-quality COVID-19 vaccines.
Related content
Comirnaty: EPAR
Comirnaty: Paediatric investigation plan
Related content
Coronavirus disease (COVID-19)
COVID-19: latest updates
COVID-19 vaccines: key facts
COVID-19 vaccines: authorised
COVID-19 vaccines: development, evaluation, approval and monitoring
Contact:
EMA press office
Tel: +31 (0)88 781 8427
E-mail: press@ema.europa.eu
(C) 2021 Electronic News Publishing, source